Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease to Assess the Safety, Tolerability, pk, and Efficacy of Pepinemab

Next Previous
Trial Profile

A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease to Assess the Safety, Tolerability, pk, and Efficacy of Pepinemab

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pepinemab (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms SIGNAL; SIGNAL-HD
  • Sponsors Vaccinex

Most Recent Events

  • 26 Sep 2023 According to a Vaccinex media release, Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimers Disease Conference to be held in Boston on October 24-27, 2023.
  • 01 Oct 2022 Results (n=265) published in the Nature Medicine
  • 08 Aug 2022 Results published in the Vaccinex Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top